Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophreniform Disorder Clear all
Completed Phase 4 Interventional Results available

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT06041646
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 21, 2026, 5:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

MicroRNAs as Biomarkers in First Episode Schizophrenia

NCT07703670
View directory record Official record
Conditions
Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Plasma NDE miRNA Sequencing, Whole Genome Sequencing
Diagnostic Test · Genetic
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 5:23 PM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Jul 21, 2026, 5:23 PM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCT02661347
View directory record Official record
Conditions
Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Risperidone, tDCS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Not applicable Interventional

A Comparative Study of New Medications for Psychosis in Adolescents

NCT00222495
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Interventions
quetiapine, olanzapine, risperidone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced Jul 21, 2026, 5:23 PM EDT
Terminated Phase 4 Interventional Results available

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

NCT04203056
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
Interventions
Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

An Integrated Program for the Treatment of First Episode of Psychosis

NCT01321177
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder, Psychotic Disorder NOS
Interventions
Integrated Treatment, Community Care
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
33
States / cities
San Fernando, California • Santa Clarita, California • Denver, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

NCT02008773
View directory record Official record
Conditions
Schizophrenia
Interventions
Valacyclovir HCI 500 mg tablets, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Bellflower, California • Los Angeles, California • Riverside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Naltrexone for Antipsychotic-Induced Weight Gain

NCT01866098
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Severe Major Depression With Psychotic Features
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

NCT00287352
View directory record Official record
Conditions
Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Interventions
Olanzapine, Amantadine, Olanzapine and placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy

NCT00791440
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Cognitive-Behavior Therapy, Standard Psychiatric Treatment
Behavioral · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Jul 21, 2026, 5:23 PM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT05658510
View directory record Official record
Conditions
Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Bellflower, California • Cerritos, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Horyzons: Implementation in Clinical Practice

NCT04673851
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
Horyzons USA
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 35 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736
View directory record Official record
Conditions
Schizophrenia (Recent-onset)
Interventions
paliperidone palmitate, risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Jul 21, 2026, 5:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Circuits in Schizophrenia and Smoking

NCT01425684
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
12 Years to 80 Years
Enrollment
837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

NCT00421954
View directory record Official record
Conditions
Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 21, 2026, 5:23 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Jul 21, 2026, 5:23 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia

NCT03061136
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Clonazepam, Placebo
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

NCT07116694
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
Interventions
BXCL501 Sublingual Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Chino, California • Oceanside, California • Orange, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Dipyridamole in Schizophrenia

NCT00349973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Dipyridamole, Olanzapine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jul 21, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI)
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Jul 21, 2026, 5:23 PM EDT
Terminated Not applicable Interventional Results available

Horyzons: Implementation and Integration in Clinical Practice

NCT06002958
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
Interventions
Horyzons USA
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 35 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jul 21, 2026, 5:23 PM EDT